CAMBRIDGE, Mass.–(BUSINESS WIRE)–Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company
in the discovery and development of TGF-beta superfamily therapeutics to
treat serious and rare diseases, today announced that members of the
management team will present at the UBS Global Healthcare Conference on
Monday, May 20th, 2019 at 11:00 a.m. EDT in New York, NY.
A live audio webcast will be available on the Investors/Media page of
the Company’s website at www.acceleronpharma.com.
A replay of the webcast will be available approximately two hours after
the event on the Acceleron website.
About Acceleron
Acceleron is a clinical-stage biopharmaceutical company dedicated to the
discovery, development, and commercialization of therapeutics to treat
serious and rare diseases. The Company’s leadership in the understanding
of TGF-beta biology and protein engineering generates innovative
compounds that engage the body’s ability to regulate cellular growth and
repair.
Acceleron focuses its research and development efforts in hematologic,
neuromuscular, and pulmonary diseases. In hematology, the Company and
its global collaboration partner, Celgene, are developing luspatercept
for the treatment of chronic anemia in myelodysplastic syndromes,
beta-thalassemia, and myelofibrosis. Acceleron is also advancing its
neuromuscular program with ACE-083, a locally-acting Myostatin+ agent in
Phase 2 development in facioscapulohumeral muscular dystrophy and
Charcot-Marie-Tooth disease and is conducting a Phase 2 pulmonary
program with sotatercept in pulmonary arterial hypertension.
For more information, please visit www.acceleronpharma.com.
Follow Acceleron on Social Media: @AcceleronPharma
and LinkedIn.
Contacts
Acceleron Pharma Inc.
Investors:
Todd James, IRC, 617-649-9393
Vice
President, Investor Relations and Corporate Communications
Media:
Matt Fearer, 617-301-9557
Director, Corporate
Communications
